Repligen (NASDAQ:RGEN) CFO Jason Garland Sells 733 Shares

Repligen Corporation (NASDAQ:RGEN) CFO Jason Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Repligen Stock Up 1.2%

Shares of NASDAQ:RGEN opened at $147.01 on Friday. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $8.29 billion, a price-to-earnings ratio of 163.35, a price-to-earnings-growth ratio of 2.80 and a beta of 1.09. The company has a 50 day moving average of $122.84 and a two-hundred day moving average of $135.54.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.25 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period last year, the firm earned $0.39 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on RGEN. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. HSBC reduced their target price on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Finally, Roth Mkm started coverage on shares of Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $164.64.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently made changes to their positions in the stock. Bayforest Capital Ltd bought a new stake in shares of Repligen in the 4th quarter worth approximately $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen during the 4th quarter worth $33,000. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the third quarter worth $29,000. Los Angeles Capital Management LLC acquired a new stake in Repligen in the fourth quarter worth $36,000. Finally, Farther Finance Advisors LLC lifted its stake in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.